Odiparcil
Based on 1 Customer Validation
Odiparcil (SB-424323) is an orally active β-D-xyloside derivative. Odiparcil can effectively divert the synthesis of cellular glycosaminoglycans (GAG) into secreted soluble species and reduce GAG accumulation. Odiparcil shows antithrombin and antiplatelet activity. Odiparcil can be used for the researches of metabolic and cardiovascular disease, such as mucopolysaccharidoses (MPS) and thrombosis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.23%
- CAS. Nr.: 137215-12-4
- Formel: C15H16O6S
- Molecular Weight:324.35
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-10787
Ximelagatran
-
HY-B0375
Argatroban
-
HY-10163
Dabigatran
-
HY-10274A
Dabigatran etexilate mesylate
-
HY-B0375A
Argatroban monohydrate
-
HY-10163R
Dabigatran (Standard)
-
HY-10277R
Odiparcil (Standard)
-
HY-129056
Melagatran
-
HY-10274
Dabigatran etexilate
-
HY-B0375R
Argatroban (Standard)
-
HY-B0209
Metolazone
-
HY-P1000
TRAP-14
Biologische Aktivität
Thrombin[2]
Odiparcil (0-10 μM) stimulates the secretion of sulphated GAG in bovine aortic endothelial cells, mainly of chondroitin sulphate (CS)/dermatan sulphate (DS) type[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Odiparcil (1.9-30 mg/kg, i.g., 3 h prior to thrombus induction) suppresses thrombus formation in rats models of venous thrombosis[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MPS VI Arsb- deficient mice models[1]
-
Dosage:1.5 and 4.5 g/kg
-
Administration:Orally administration, daily
-
Result:Consistently stimulated the urinary excretion of sulphated GAG.
Reduced liver and kidney sulphated GAG accumulation.
Diminished the pathological cartilage thickening in trachea and femoral growth plates.
Reduced accumulation of granules in leukocytes.
-
Animal Model:Rats models of venous thrombosis[2]
-
Dosage:1.9, 3.8, 7.5. 15 and 30 mg/kg
-
Administration:Orally gavage, 3 h prior to thrombus induction
-
Result:Produced dose-related suppression of thrombus formation.
Resulted in 40% inhibition of thrombin activity.
Did not cause dose-related changes in bleeding time or blood loss.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 137215-12-4
-
Appearance Solid
-
Molecular Weight 324.35
-
Formel C15H16O6S
-
Color White to off-white
-
SMILES
CC(C1=CC=C(O[C@H]2[C@@H]([C@H]([C@@H](CS2)O)O)O)C=C1O3)=CC3=O
-
Synonyms
SB-424323
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (308.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.71 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Entchev E, et al. Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models. PLoS One. 2020 May 15;15(5):e0233032. [Content Brief]
[2]. Toomey JR, et al. A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis. J Thromb Haemost. 2006 Sep;4(9):1989-96. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0831 mL | 15.4154 mL | 30.8309 mL | 77.0772 mL |
| 5 mM | 0.6166 mL | 3.0831 mL | 6.1662 mL | 15.4154 mL | |
| 10 mM | 0.3083 mL | 1.5415 mL | 3.0831 mL | 7.7077 mL | |
| 15 mM | 0.2055 mL | 1.0277 mL | 2.0554 mL | 5.1385 mL | |
| 20 mM | 0.1542 mL | 0.7708 mL | 1.5415 mL | 3.8539 mL | |
| 25 mM | 0.1233 mL | 0.6166 mL | 1.2332 mL | 3.0831 mL | |
| 30 mM | 0.1028 mL | 0.5138 mL | 1.0277 mL | 2.5692 mL | |
| 40 mM | 0.0771 mL | 0.3854 mL | 0.7708 mL | 1.9269 mL | |
| 50 mM | 0.0617 mL | 0.3083 mL | 0.6166 mL | 1.5415 mL | |
| 60 mM | 0.0514 mL | 0.2569 mL | 0.5138 mL | 1.2846 mL | |
| 80 mM | 0.0385 mL | 0.1927 mL | 0.3854 mL | 0.9635 mL | |
| 100 mM | 0.0308 mL | 0.1542 mL | 0.3083 mL | 0.7708 mL |
Odiparcil Related Classifications
HY-10277 Related Classifications
Powered by Bioz